Development of an immuno-lectin-enzymatic assay for the detection of serum cancer-associated glycoproteins bearing Tn determinant

• DOI: 10.3892/ijo.8.2.401
• Publication Date: 2014-03-10T07:22:41Z
• Authors: E Osinaga; A Babino; J Grosclaude; E Cairoli; C Batthyany; S Bianchi; S Signorelli; M Varangot; I Muse; A Roseto
• Keywords: [SDV] Life Sciences [q-bio]; 0301 basic medicine; 03 medical and health sciences; [SDV]Life Sciences [q-bio]; CANCER; 3. Good health

We report the development of an immuno-lectin-enzymatic assay (CA83.4) with purpose quantifying serum glycoproteins bearing Tn determinant (GalNAc alpha-O-Ser/Thr). An anti-Tn monoclonal antibody (83D4) is bound to solid phase in order capture glycoproteins. After addition a test sample, we used biotinylated isolectin B4 from Vicia villosa and avidin-peroxydase act as detection system. The linear relationship between CA83.4 determinations dilutions, reproducibility dosage intra- inter-assay, specificity for N-acetylgalactosamine residue a-glycosidic O-linkages, demonstrated reliability this trial. Self-recognition molecules (K-D: 0.73x10(-6) M determined using biosensor technology) could determine additional step signal amplification assay. Using 0.25 units/ml antigen cut-off level, higher values were found 25/49 patients breast cancer, 8/13 colorectal carcinoma, 3/11 lung but none 49 non-malignant diseases nor 97 healthy controls. This first on soluble Tn-glycoprotein assays suggests that Tn-glycoproteins are specific serological tumor markers believe they represent valuable tool diagnosis cancer.